Rein Therapeutics, Inc.
RNTXNasdaq
$0.86
↑ +0.0%Jul 17 close · end-of-day
Price
1Y↓ -40.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$26.2M
Enterprise Value
$21.7M
P/E
—
P/S
—
P/B
2.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
0.0%
Revenue (TTM)
$0.00
Net Income (TTM)
-$50.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-433.4%
ROIC
-555.5%
Debt / Equity
—
Net Cash
$4.4M
Return 1Y
-38.4%
Company profile
Rein Therapeutics Inc is a biopharmaceutical company that focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. They are headquartered in Austin, Texas.
- CEO
- Manuel C. Alves Aivado
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 9
- Headquarters
- Texas
- Website
- aileronrx.com
Earnings
RNTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.19↓ -24.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.5M | -$26.6M | -$27.6M | -$16.3M | -$65.1M | -$50.6M |
| Net income | -$27.3M | -$26.2M | -$27.3M | -$15.7M | -$62.9M | -$49.9M |
| Diluted EPS | — | -$5.89 | -$6.02 | -$3.42 | -$3.51 | -$1.96 |
| Operating cash flow | -$20.5M | -$23.8M | -$24.9M | -$19.8M | -$22.3M | -$19.4M |
| Free cash flow | -$20.5M | -$23.9M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$9.0M | -$6.1M | -$42.8M | -$5.6M | -$6.9M | -$5.5M | -$32.7M | -$5.2M |
| Net income | -$8.9M | -$5.8M | -$41.0M | -$5.5M | -$6.8M | -$5.6M | -$32.0M | -$5.8M |
| Diluted EPS | -$0.45 | -$0.27 | -$1.93 | -$0.25 | -$0.28 | -$0.21 | -$1.22 | -$0.19 |
| Operating cash flow | -$8.4M | -$3.8M | -$4.8M | -$6.2M | -$6.4M | -$3.5M | -$3.2M | -$3.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 17, 2026
Jun 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-27 | VON RICKENBACH JOSEF H | Buy | 4,500 | $1.07 | $4,818.60 | filing |
| 2026-05-26 | VON RICKENBACH JOSEF H | Buy | 23,190 | $1.06 | $24,470.09 | filing |
| 2026-05-22 | VON RICKENBACH JOSEF H | Buy | 15,950 | $1.05 | $16,707.63 | filing |
| 2026-05-21 | VON RICKENBACH JOSEF H | Buy | 3,420 | $1.04 | $3,564.32 | filing |
| 2026-04-30 | WINDSOR JAMES BRIAN· See Remarks | Buy | 25,000 | $1.00 | $25,000.00 | filing |
| 2025-11-14 | Voss Capital LLC | Buy | 104,183 | $1.22 | $127,592.92 | filing |
| 2025-10-28 | Voss Capital LLC | Buy | 178,392 | $1.39 | $247,964.88 | filing |
| 2025-10-27 | Voss Capital LLC | Buy | 92,642 | $1.37 | $126,919.54 | filing |
| 2025-10-27 | Voss Capital LLC | Buy | 4,840 | $1.37 | $6,624.51 | filing |
| 2025-10-24 | Voss Capital LLC | Buy | 30,176 | $1.39 | $41,956.71 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.